Research programme: Sn 117m-labelled mannose receptor-targeted diagnostics and therapeutics - R-NAV

Drug Profile

Research programme: Sn 117m-labelled mannose receptor-targeted diagnostics and therapeutics - R-NAV

Alternative Names: Sn 117m tilmanocept - R-NAV; Tin-117m tilmanocept - R-NAV; Tin-117m-labelled mannose receptor-targeted diagnostics and therapeutics - R-NAV

Latest Information Update: 21 Jul 2014

Price : $50

At a glance

  • Originator R-NAV
  • Class Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Macrophage modulators; Mannose receptor modulators; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Joint disorders; Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2014 Early research in Rheumatoid arthritis in USA (unspecified route)
  • 16 Jul 2014 Early research in Osteoarthritis (diagnosis) in USA (unspecified route)
  • 16 Jul 2014 Early research in Rheumatoid arthritis (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top